<qa>  What is the maximum tolerated dose defined by?This is a Phase I, multicenter, dose-escalation study of MDX-1100 anti-CXCL10 human monoclonal antibody in patients with UC, as defined by standard clinical, endoscopic and histological criteria and a DAI greater than or equal to 4 and less than or equal to 9. Three to six patients will be entered into each of 4 cohorts 0.3, 1.0, 3.0 or 10mgkg. Starting with the lowest dose cohort 0.3mgkg, patients will be administered a single dose of MDX-1100 at Day 1 and will be followed until 70 days from the last dose. Dose escalation may proceed when the third patient in the cohort has reached Day 29 and if no dose-limiting toxicities DLTs have occurred. Dose escalation may proceed when the sixth patient reaches Day 29 and 2 DLTs have occurred in the cohort. Dose escalation will continue until the last cohort is enrolled or the maximum tolerated dose MTD is defined. 